High vs . Standard Radiotherapy Dose in Locally Advanced Rectal Adenocarcinoma Patients Treated With Neoadjuvant Long Course Chemoradiotherapy: A Population-based Study.
- Resource Type
- Academic Journal
- Authors
- Liang JA; Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan, R.O.C.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C.; Kuo YC; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C.; Department of Radiation Oncology, China Medical University Hsinchu Hospital, Hsinchu, Taiwan, R.O.C.; Chao KSC; Cancer Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.; Chen WT; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C.; Department of Surgery, China Medical University Hsinchu Hospital, Hsinchu, Taiwan, R.O.C.; Department of Colorectal Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.; Ke TW; Department of Colorectal Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.; School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan, R.O.C.; Chou SH; Department of Medical Imaging, China Medical University Hsinchu Hospital, Hsinchu, Taiwan, R.O.C.; Li CC; Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan, R.O.C.; Chien CR; Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan, R.O.C.; d16181@gmail.com.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C.
- Source
- Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE
- Subject
- Language
- English
Background/aim: Locally advanced rectal cancer (LARC) patients are often treated with neoadjuvant long course chemoradiotherapy (NLCCRT) using 45-50.4 Gy conventional fractionated radiotherapy (CFRT). The role of radiotherapy dose escalation is unclear.
Patients and Methods: We identified LARC patients diagnosed from 2011 to 2016 and treated with NLCCRT using CFRT at high dose (54-60 Gy) or standard dose (45-50.4 Gy). In the primary analyses, we used propensity score (PS) weighting to balance the observable potential confounders. The hazard ratio (HR) of death and other endpoints were compared. We also evaluated these outcomes in supplementary analyses via an alternative approach.
Results: Our primary analysis included 459 patients. The HR of death when high dose was compared with standard dose was 0.62 (p=0.51). There were also no statistically significant differences in other endpoints or in the supplementary analyses.
Conclusion: Overall, survival of LARC patients treated with NLCCT in CFRT was not significantly different between high or standard dose.
(Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)